Novel neurotransmitters and their neuropsychiatric relevance

S. H. Snyder, C. D. Ferris

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this review is to integrate insights regarding novel neurotransmitters or neuromodulators of neuropsychiatric significance. Method: Evolving concepts of neurotransmitter criteria are reviewed in light of the unexpected properties displayed by recently identified transmitters. Results: Classic criteria for transmitters were based on the properties of acetylcholine but were markedly revised with the recognition of the catecholamines, serotonin, γ-aminobutyric acid (GABA), and other amino acid transmitters and neuropeptides. Nitric oxide and carbon monoxide are notably atypical, as they are not stored in synaptic vesicles, are not released by exocytosis, and do not act at postsynaptic membrane receptor proteins. D-Serine, recently appreciated as the endogenous ligand for the glycine site of the glutamate N-methyl-D-aspartate (NMDA) receptor, overturns fundamental axioms of biology as well as those of neuroscience. It is a D-amino acid, and it is synthesized and stored in gila rather than neurons. Released glutamate acts on receptors on the protoplasmic astrocytes closely apposed to the synapse to release D-serine, which coactivates postsynaptic NMDA receptors together with glutamate. D-Serine is formed by serine racemase, which directly converts L-serine to D-serine. Inhibitors of this enzyme should reduce NMDA neurotransmission and might be therapeutic in stroke and other conditions associated with glutamate excitotoxicity. Conclusions: The diversity of novel neurotransmitters and venues of their activity afford multiple opportunities for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)1738-1751
Number of pages14
JournalAmerican Journal of Psychiatry
Volume157
Issue number11
DOIs
StatePublished - 2000

Fingerprint

Serine
Neurotransmitter Agents
Glutamic Acid
N-Methyl-D-Aspartate Receptors
Aminobutyrates
Amino Acids
Synaptic Vesicles
Exocytosis
Enzyme Inhibitors
N-Methylaspartate
Carbon Monoxide
Neurosciences
Neuropeptides
Synaptic Transmission
Astrocytes
Synapses
Glycine
gamma-Aminobutyric Acid
Acetylcholine
Catecholamines

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Novel neurotransmitters and their neuropsychiatric relevance. / Snyder, S. H.; Ferris, C. D.

In: American Journal of Psychiatry, Vol. 157, No. 11, 2000, p. 1738-1751.

Research output: Contribution to journalArticle

@article{f521bb799b9f4c2bbebc1a601d3489b6,
title = "Novel neurotransmitters and their neuropsychiatric relevance",
abstract = "Objective: The purpose of this review is to integrate insights regarding novel neurotransmitters or neuromodulators of neuropsychiatric significance. Method: Evolving concepts of neurotransmitter criteria are reviewed in light of the unexpected properties displayed by recently identified transmitters. Results: Classic criteria for transmitters were based on the properties of acetylcholine but were markedly revised with the recognition of the catecholamines, serotonin, γ-aminobutyric acid (GABA), and other amino acid transmitters and neuropeptides. Nitric oxide and carbon monoxide are notably atypical, as they are not stored in synaptic vesicles, are not released by exocytosis, and do not act at postsynaptic membrane receptor proteins. D-Serine, recently appreciated as the endogenous ligand for the glycine site of the glutamate N-methyl-D-aspartate (NMDA) receptor, overturns fundamental axioms of biology as well as those of neuroscience. It is a D-amino acid, and it is synthesized and stored in gila rather than neurons. Released glutamate acts on receptors on the protoplasmic astrocytes closely apposed to the synapse to release D-serine, which coactivates postsynaptic NMDA receptors together with glutamate. D-Serine is formed by serine racemase, which directly converts L-serine to D-serine. Inhibitors of this enzyme should reduce NMDA neurotransmission and might be therapeutic in stroke and other conditions associated with glutamate excitotoxicity. Conclusions: The diversity of novel neurotransmitters and venues of their activity afford multiple opportunities for therapeutic intervention.",
author = "Snyder, {S. H.} and Ferris, {C. D.}",
year = "2000",
doi = "10.1176/appi.ajp.157.11.1738",
language = "English (US)",
volume = "157",
pages = "1738--1751",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "11",

}

TY - JOUR

T1 - Novel neurotransmitters and their neuropsychiatric relevance

AU - Snyder, S. H.

AU - Ferris, C. D.

PY - 2000

Y1 - 2000

N2 - Objective: The purpose of this review is to integrate insights regarding novel neurotransmitters or neuromodulators of neuropsychiatric significance. Method: Evolving concepts of neurotransmitter criteria are reviewed in light of the unexpected properties displayed by recently identified transmitters. Results: Classic criteria for transmitters were based on the properties of acetylcholine but were markedly revised with the recognition of the catecholamines, serotonin, γ-aminobutyric acid (GABA), and other amino acid transmitters and neuropeptides. Nitric oxide and carbon monoxide are notably atypical, as they are not stored in synaptic vesicles, are not released by exocytosis, and do not act at postsynaptic membrane receptor proteins. D-Serine, recently appreciated as the endogenous ligand for the glycine site of the glutamate N-methyl-D-aspartate (NMDA) receptor, overturns fundamental axioms of biology as well as those of neuroscience. It is a D-amino acid, and it is synthesized and stored in gila rather than neurons. Released glutamate acts on receptors on the protoplasmic astrocytes closely apposed to the synapse to release D-serine, which coactivates postsynaptic NMDA receptors together with glutamate. D-Serine is formed by serine racemase, which directly converts L-serine to D-serine. Inhibitors of this enzyme should reduce NMDA neurotransmission and might be therapeutic in stroke and other conditions associated with glutamate excitotoxicity. Conclusions: The diversity of novel neurotransmitters and venues of their activity afford multiple opportunities for therapeutic intervention.

AB - Objective: The purpose of this review is to integrate insights regarding novel neurotransmitters or neuromodulators of neuropsychiatric significance. Method: Evolving concepts of neurotransmitter criteria are reviewed in light of the unexpected properties displayed by recently identified transmitters. Results: Classic criteria for transmitters were based on the properties of acetylcholine but were markedly revised with the recognition of the catecholamines, serotonin, γ-aminobutyric acid (GABA), and other amino acid transmitters and neuropeptides. Nitric oxide and carbon monoxide are notably atypical, as they are not stored in synaptic vesicles, are not released by exocytosis, and do not act at postsynaptic membrane receptor proteins. D-Serine, recently appreciated as the endogenous ligand for the glycine site of the glutamate N-methyl-D-aspartate (NMDA) receptor, overturns fundamental axioms of biology as well as those of neuroscience. It is a D-amino acid, and it is synthesized and stored in gila rather than neurons. Released glutamate acts on receptors on the protoplasmic astrocytes closely apposed to the synapse to release D-serine, which coactivates postsynaptic NMDA receptors together with glutamate. D-Serine is formed by serine racemase, which directly converts L-serine to D-serine. Inhibitors of this enzyme should reduce NMDA neurotransmission and might be therapeutic in stroke and other conditions associated with glutamate excitotoxicity. Conclusions: The diversity of novel neurotransmitters and venues of their activity afford multiple opportunities for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=0033765902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033765902&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.157.11.1738

DO - 10.1176/appi.ajp.157.11.1738

M3 - Article

C2 - 11058466

AN - SCOPUS:0033765902

VL - 157

SP - 1738

EP - 1751

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 11

ER -